London-based AstraZeneca has agreed to buy a respiratory business from Japan’s Takeda Pharmaceutical for $575 million to gain global rights to the lung treatment roflumilast.
AstraZeneca currently markets roflumilast in the U.S. under the brand name Daliresp. The new deal will help AstraZeneca grow its Japan operations, as well as give the drugmaker access to promising pipeline products.
Simultaneously, AstraZeneca also announced an alliance with China’s WuXi AppTec, a research and development platform, to investigate biological medicines.
Read the Bloomberg press release